COX-2 (cyclooxygenase-2) is an enzyme your body produces mainly in response to injury or inflammation. Its job is to convert a fatty acid called arachidonic acid into prostaglandins, which are chemical messengers that trigger pain, swelling, and fever. While COX-2 plays a central role in inflammation, it also has quieter jobs in healthy tissue, particularly in the brain, kidneys, and uterus. Understanding COX-2 matters because it’s the specific target of many common pain medications.
How COX-2 Works in Your Body
Your cells contain arachidonic acid in their membranes. When tissue is damaged or irritated, COX-2 acts as the rate-limiting step in converting that fatty acid into prostaglandins. These prostaglandins do several things at once: they dilate blood vessels near the injury site, make nerve endings more sensitive to pain, and raise local temperature. This is the redness, swelling, and tenderness you feel during inflammation.
COX-2 is sometimes called an “inducible” enzyme because your body doesn’t keep large amounts of it on hand at all times. Instead, immune cells and damaged tissues ramp up COX-2 production rapidly when triggered by signals from the immune system, such as cytokines and growth factors. Bacterial infections can also trigger it. Once the threat or injury resolves, COX-2 levels drop back down.
That said, COX-2 isn’t purely an inflammation enzyme. Small amounts are continuously active in the brain, kidneys, and uterus under normal conditions. In the kidneys, COX-2-derived prostaglandins help maintain blood flow, regulate sodium excretion, and control the release of renin, a hormone involved in blood pressure. This dual nature, both protective and inflammatory, is what makes targeting COX-2 with drugs more complicated than it first appears.
COX-2 Versus COX-1
Your body actually has two versions of the cyclooxygenase enzyme. COX-1 is the “always on” version, present at steady levels in nearly every tissue: the stomach lining, kidneys, blood vessels, and platelets. It handles housekeeping tasks like protecting the stomach from its own acid and helping platelets clump together to form blood clots.
COX-2, by contrast, runs at low levels most of the time and surges during inflammation. The key differences break down like this:
- Expression pattern: COX-1 is constitutive (always present). COX-2 is inducible (produced on demand).
- Location: COX-1 is found in almost all tissues, especially the GI tract and platelets. COX-2 is normally active only in a few organs like the brain and kidneys, but can appear anywhere inflammation occurs.
- Primary role: COX-1 maintains day-to-day functions. COX-2 drives the inflammatory response.
- Platelets: COX-1 is the only version found in platelets, where it produces thromboxane, a compound that promotes clotting. COX-2 is absent from platelets entirely.
This distinction is exactly why drug developers wanted to create medications that block COX-2 without touching COX-1. Traditional painkillers like ibuprofen and naproxen block both enzymes, which reduces inflammation but also strips away COX-1’s protective effects on the stomach lining, leading to ulcers and GI bleeding in some people.
COX-2 Inhibitors as Medications
Selective COX-2 inhibitors were developed in the 1990s to relieve pain and inflammation while sparing the stomach. Celecoxib (brand name Celebrex) is currently the only COX-2 inhibitor available in the United States. Outside the U.S., etoricoxib (Arcoxia) and parecoxib (Dynastat) are also available.
These drugs are approved to treat mild-to-moderate pain and inflammation from osteoarthritis, rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, menstrual pain, and short-term injuries like sports-related strains. They’re also used for a rare inherited condition called familial adenomatous polyposis. Some providers prescribe them off-label for gout or migraines.
On the stomach safety front, COX-2 inhibitors do deliver. In head-to-head trials, the rate of serious upper GI events (bleeding, perforation, ulcers) was about 31% lower with a COX-2 inhibitor compared to a traditional anti-inflammatory drug. For people with a history of stomach ulcers or GI bleeding, that difference can be significant.
The Cardiovascular Risk
The story of COX-2 inhibitors took a sharp turn in 2004, when Merck voluntarily pulled rofecoxib (Vioxx) from the market. A clinical trial called APPROVe, which was testing whether Vioxx could prevent colon polyps, found an increased risk of heart attacks and strokes in patients taking the drug. The elevated risk appeared after about 18 months of continuous use, and the trial was stopped early.
The underlying mechanism helps explain why this happened. COX-2 normally produces prostacyclin in blood vessel walls. Prostacyclin keeps blood vessels relaxed and discourages platelets from clumping. When you selectively block COX-2 but leave COX-1 alone, you remove the prostacyclin brake while leaving thromboxane (the COX-1 product in platelets that promotes clotting) fully intact. This imbalance can tip the cardiovascular system toward blood clots, higher blood pressure, and accelerated artery disease.
This is why celecoxib, the remaining COX-2 inhibitor on the U.S. market, carries warnings about cardiovascular risk, particularly for people who already have heart disease or multiple risk factors. It’s generally prescribed at the lowest effective dose for the shortest time needed.
Effects on the Kidneys
Because COX-2 is constitutively active in kidney tissue, blocking it can interfere with normal kidney function. COX-2 inhibitors can cause sodium retention, meaning your kidneys hold onto more salt and water than usual. In studies, this effect typically shows up within the first 72 hours of starting the medication. For most people with healthy kidneys, this is temporary and mild. But in people with existing kidney problems or those on a high-salt diet, COX-2 inhibitors can worsen high blood pressure or contribute to fluid retention.
Animal studies have shown that blocking COX-2 specifically in the kidney’s inner tissue directly induces hypertension when salt intake is high. This kidney connection is one reason COX-2 inhibitors aren’t considered safe for long-term use in people with kidney disease.
COX-2 and Cancer
COX-2 also plays a role in certain cancers, particularly colorectal cancer. Studies of tumor tissue show that roughly 80% of colorectal cancers overexpress COX-2, and higher COX-2 levels correlate with more advanced disease stages, deeper tumor invasion, and a greater likelihood of metastasis to lymph nodes and the liver. In one study of 45 colorectal cancers that had spread to lymph nodes, 87% of the primary tumors were COX-2 positive, and 100% of the metastatic deposits in lymph nodes showed COX-2 activity.
The connection appears to work through several pathways. COX-2 promotes the growth of new blood vessels that feed tumors, a process called angiogenesis. It also helps cancer cells resist programmed cell death and increases their ability to invade surrounding tissue. Tumors with high COX-2 expression tend to also produce high levels of proteins that break down the tissue barriers that normally keep cells in place, making it easier for cancer to spread.
This is partly why celecoxib is approved for familial adenomatous polyposis, a genetic condition that causes hundreds of precancerous colon polyps. However, the cardiovascular risks of long-term COX-2 inhibition limit how broadly these drugs can be used as a cancer prevention strategy.